サルコペニア(Sarcopenia)の治療薬パイプライン動向(2015年上半期版)

【英語タイトル】Sarcopenia - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6063IDB)・商品コード:GMDHC6063IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月22日
・ページ数:61
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるサルコペニア(Sarcopenia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・サルコペニア(Sarcopenia)の概要
・サルコペニア(Sarcopenia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・サルコペニア(Sarcopenia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・サルコペニア(Sarcopenia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・サルコペニア(Sarcopenia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Sarcopenia – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Sarcopenia – Pipeline Review, H1 2015’, provides an overview of the Sarcopenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Sarcopenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sarcopenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sarcopenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sarcopenia Overview 7
Therapeutics Development 8
Pipeline Products for Sarcopenia – Overview 8
Pipeline Products for Sarcopenia – Comparative Analysis 9
Sarcopenia – Therapeutics under Development by Companies 10
Sarcopenia – Therapeutics under Investigation by Universities/Institutes 11
Sarcopenia – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Sarcopenia – Products under Development by Companies 14
Sarcopenia – Products under Investigation by Universities/Institutes 15
Sarcopenia – Companies Involved in Therapeutics Development 16
Calzada Limited 16
Cytokinetics, Inc. 17
GlaxoSmithKline plc 18
Myos Corporation 19
Neurotune AG 20
Novartis AG 21
PsiOxus Therapeutics, Ltd. 22
Regeneron Pharmaceuticals, Inc. 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Sarcopenia – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AOD-9604 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bimagrumab – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CK-2066260 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MT-102 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NEP-28 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NT-1654 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Protein for Musculoskeletal Disorders – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Recombinant Protein for Sarcopenia – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REGN-1033 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
S-107 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Sarcopenia – Recent Pipeline Updates 50
Sarcopenia – Dormant Projects 53
Sarcopenia – Discontinued Products 54
Sarcopenia – Product Development Milestones 55
Featured News & Press Releases 55
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 55
Dec 14, 2011: Calzada Announces New Applications For AOD9604 55
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 56
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 57
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

[List of Tables]
Number of Products under Development for Sarcopenia, H1 2015 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Sarcopenia - Pipeline by Calzada Limited, H1 2015 16
Sarcopenia - Pipeline by Cytokinetics, Inc., H1 2015 17
Sarcopenia - Pipeline by GlaxoSmithKline plc, H1 2015 18
Sarcopenia - Pipeline by Myos Corporation, H1 2015 19
Sarcopenia - Pipeline by Neurotune AG, H1 2015 20
Sarcopenia - Pipeline by Novartis AG, H1 2015 21
Sarcopenia - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 22
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 23
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Sarcopenia Therapeutics - Recent Pipeline Updates, H1 2015 50
Sarcopenia - Dormant Projects, H1 2015 53
Sarcopenia - Discontinued Products, H1 2015 54

[List of Figures]
Number of Products under Development for Sarcopenia, H1 2015 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

【掲載企業】

Calzada Limited
Cytokinetics, Inc.
GlaxoSmithKline plc
Myos Corporation
Neurotune AG
Novartis AG
PsiOxus Therapeutics, Ltd.
Regeneron Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.

★調査レポート[サルコペニア(Sarcopenia)の治療薬パイプライン動向(2015年上半期版)] (コード:GMDHC6063IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[サルコペニア(Sarcopenia)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆